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Abstract
Background: Pancreatic cancer stem cells (CSCs) represent a small subpopulation of pancreatic cancer cells that have the
capacity to initiate and propagate tumor formation. However, the mechanisms by which pancreatic CSCs are maintained are
not well understood or characterized.
Methods: Expression of Notch receptors, ligands, and Notch signaling target genes was quantitated in the CSC and non-CSC
populations from 8 primary human pancreatic xenografts. A gamma secretase inhibitor (GSI) that inhibits the Notch
pathway and a shRNA targeting the Notch target gene Hes1 were used to assess the role of the Notch pathway in CSC
population maintenance and pancreatic tumor growth.
Results: Notch pathway components were found to be upregulated in pancreatic CSCs. Inhibition of the Notch pathway
using either a gamma secretase inhibitor or Hes1 shRNA in pancreatic cancer cells reduced the percentage of CSCs and
tumorsphere formation. Conversely, activation of the Notch pathway with an exogenous Notch peptide ligand increased
the percentage of CSCs as well as tumorsphere formation. In vivo treatment of orthotopic pancreatic tumors in NOD/SCID
mice with GSI blocked tumor growth and reduced the CSC population.
Conclusion: The Notch signaling pathway is important in maintaining the pancreatic CSC population and is a potential
therapeutic target in pancreatic cancer.
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Introduction
Pancreatic cancer is the fourth most common cause of cancer-
related death in the United States despite being the 10th most
common cancer diagnosis [1]. The high mortality rate is partly
due to the fact that the vast majority of pancreatic cancers are
diagnosed at an advanced stage. But at least equally important is
that pancreatic cancers are generally only minimally responsive to
chemotherapy and radiotherapy. There is increasing evidence that
this resistance to therapy is at least in part due to the inherent
resistance of a subpopulation of cancer cells that are tumorigenic
and share many properties with stem cells and thus have been
labeled cancer stem cells (CSC). Cancer stem cells were first
isolated in myeloid leukemia [2] and were shown to share stem cell
properties such as potential for self-renewal and the ability to
differentiate and proliferate. Subsequently, CSCs have also been
identified in a wide range of solid tumors including breast, brain,
liver, colon, prostate, melanoma, and pancreatic tumors [3–
10]_ENREF_3. Pancreatic cancer stem cells (CSC) were first
isolated from human pancreatic cancers using the marker profile
ESA+/CD44+/CD24+ [10]. These marker positive CSCs were
able to form tumors in NOD/SCID mice that appeared
histologically similar to the primary tumor, suggesting multi-
potency with reconstitution of the various tumor cell types. In vitro
evidence for a stem cell phenotype such as self-renewal was
demonstrated by the ability to form tumor spheres in vitro in
contrast to ESA-/CD44-/CD24- cells which could not.
It remains incompletely understood how pancreatic cancer stem
cells are maintained in a heterogeneous tumor. One potential
contributor to CSC maintenance is the Notch signaling pathway.
In the normal developing pancreas, the Notch signaling pathway
has been shown to be an important regulator of the balance
between self-renewal and differentiation [11–13]. There are 4
members of the mammalian Notch receptor family (NOTCH 1–4)
which are similarly processed and activated through a series of
cleavage events. The mature Notch receptor is composed of two
subunits that are generated as a result of an initial cleavage event
by furin-like convertase [14]. Notch signaling pathway activation
occurs when a Notch receptor binds to one of the five known
Notch ligands [jagged1 (JAG1), jagged2 (JAG2), delta-like 1
(DLL1), delta-like 3 (DLL3), and delta-like 4 (DLL4)]. Ligand
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binding causes a conformational change in the Notch receptor
which allows a second cleavage by tumor necrosis factor-alpha-
converting enzyme (TACE) [15]. A third cleavage event is carried
out by a gamma secretase (presenilin), which releases the
intracellular domain of Notch allowing it to translocate to the
nucleus to activate expression of target genes [16].
Inhibition of the Notch signaling pathway results in depletion of
multi-potent pancreatic progenitor cells [11,13]. Conversely,
induced Notch activation prevents pancreatic epithelial differen-
tiation and results in increased maintenance of undifferentiated
pancreatic progenitor cells [12]. Based on similar phenotypic
characteristics exhibited by CSCs, the Notch signaling pathway
has been evaluated for its role in CSC self-renewal. Both breast
and brain CSCs have been shown to have increased Notch
pathway activation [17,18]. In vitro inhibition of the Notch
signaling pathway in these two tumor types results in decreased
self-renewal, shown by reduction in tumorsphere formation. We
hypothesized that the Notch signaling pathway is further
upregulated in pancreatic CSC and contributes to pancreatic
CSC function and pancreatic cancer tumorigenesis.
In this study, we evaluated the role of the Notch pathway in
maintaining the CSC population and its effects of inhibition in
pancreatic tumor growth. We detect upregulation of several Notch
pathway components in pancreatic CSCs and demonstrate that
inhibition by a gamma secretase inhibitor or shRNA to Hes1, a
key Notch target gene, reduces pancreatic CSC self-renewal and
tumorigenicity. In vivo treatment of established orthotopic
pancreatic tumors with a gamma secretase inhibitor reduces
tumor growth and combination with cytotoxic chemotherapy
further augments the anti-tumor response. Our results suggest that
Notch signaling is critical for pancreatic CSC maintenance and
that targeting the Notch signaling pathway in pancreatic cancer
has promising therapeutic potential.
Materials and Methods
Ethics Statement
Pancreatic adenocarcinoma tissue samples were obtained from
patients that underwent surgical procedures within the University
of Michigan Health System. Written informed consent from all
research subjects was obtained prior to collection of tissue, and all
protocols involving patient samples were reviewed and approved
by the Institutional Review Boards of the University of Michigan
Medical School (IRBMED). Original, hardcopies of all written
informed consent forms are kept within a secure file at the
University of Michigan. The Institutional Review Boards of the
University of Michigan Medical School (IRBMED) determined
that this study conforms to applicable guidelines, state and federal
regulations, and the University of Michigan’s Federalwide
Assurance (FWA) with the Department of Health and Human
Services (HHS). The IRBMED also approved all written consent
documents, as well as consent procedures, for this study. The
University of Michigan Federalwide Assurance number for this
study is FWA00004969, and the Study University of Michigan
study identification number is HUM00025339.
Antibodies and reagents
Merck gamma secretase inhibitor (MK-0752) was provided by
Dr. Max Wicha (University of Michigan) and was used for the in
vitro and ex vivo studies. Gamma secretase inhibitor RO4929097
was kindly provided by Roche (Indianapolis, IN) and was used for
the in vivo studies. PE-conjugated mouse anti-human CD44 and
FITC-conjugated mouse anti-human CD24 antibodies were
purchased from B.D. (Franklin Lakes, NJ). APC conjugated
mouse anti-human ESA was purchased from Miltenyi Biotech and
biotinylated mouse anti-mouse H2K was purchased from South-
ern Biotech. Hes1 antibody used for Western Blot was obtained
from Dr. Xing Fan (University of Michigan) or purchased from
MBL International (Woburn, MA). Notch1 and cleaved Notch1
antibodies were purchased from Cell Signaling Technology
(Danvers, MA) and b-actin antibody was purchased from Sigma
(St. Louis, MO). Matrigel was purchased from B.D. (Franklin
Lakes, NJ). Hes1 shRNA clone V2LHS 249784 was purchased
from Open Biosystems (Huntsville, AL). The delta/Serrate/Lag-2
(DSL) peptide (sequence CDDYYYGFGCNKFCRPR) was syn-
thesized by the University of Michigan Protein Structure Facility.
Protocol approval
Animal protocols were approved by University Committee for
the Use and Care of Animals (UCUCA) at University of Michigan
and lentivirus protocols were approved by Institutional Biosafety
Committee (IBC) at University of Michigan.
Preparation of single cell suspensions of tumor cells
Single cell suspension of tumor cells was prepared as described
[10] with the following modifications. Primary human pancreatic
adenocarcinoma xenograft tissue was minced completely and then
suspended in 200 Unit/mL ultrapure collagenase IV (Worthing-
ton Biochemicals, Freehold, NJ) in Media 199 (Invitrogen,
Carlsbad, CA). After enzyme digestion at 37uC for 45 to 60
minutes and mechanical dissociation by pipetting every 15 minutes
with a 10 mL pipette, the digested and dissociated cells were
filtered through a 40 mm nylon mesh cell restrictor (B.D. Franklin
Lakes, NJ) and washed with HBSS (Invitrogen, Carlsbad, CA)
twice. The cells were then resuspended in 2% FBS in HBSS for
experiments.
Flow cytometry
Flow cytometry was performed as described previously [10].
Dissociated cells were counted and transferred to 5 mL tubes,
washed with HBSS/2%FBS twice and resuspended in HBSS/2%
FBS at a concentration of 1 million cells per 100 mL. Sandoglobin
(1 mg/mL) was added to the sample at a dilution of 1:50 and the
sample was incubated on ice for 20 min, then washed twice with
HBSS/2%FBS. Antibodies PE-conjugated mouse anti-human
CD44, FITC-conjugated mouse anti-human CD24, APC conju-
gated mouse anti- human ESA and biotinylated mouse anti-mouse
H2K were added at the dilution as instructed, and the sample was
incubated for 45 min on ice and then washed twice with HBSS/
2%FBS. Streptavidin conjugated with APC-Cy7 was added at the
dilution of 1:200 and the sample was incubated on ice for 15
minutes. After washing twice with HBSS/2%FBS, cells were
resuspended in HBSS/2%FBS containing 3 mM 49,6-diamidino-
2-phenylindole (DAPI) (Invitrogen, Carlsbad, CA). Flow cytome-
try was done using a FACSAria (B.D., Franklin Lakes, NJ). Side
scatter and forward scatter profiles were used to eliminate cell
doublets.
Quantitative PCR
Primers for Notch pathway components were selected from a
primer bank (Wang & Seed, 2003) and synthesized by Invitrogen
(Carlsbad, CA). Total RNA was extracted from sorted cancer stem
cells and non-cancer stem cells using a RNeasy Micro kit (Qiagen,
Valencia, CA) as instructed. Reverse transcription of cDNA was
performed using High-Capacity cDNA Reverse Transcription
Kits (Applied Biosystems, Foster City, CA) as instructed. qPCR
was performed on Rotorgene 6000 (Qiagen, Valencia, CA) using a
Notch Pathway in Pancreatic Cancer Stem Cells
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Power SYBR Green PCR Master Mix (Applied Biosystem, Foster
City, CA) per the manufacturer’s instructions, with all reactions
normalized to GAPDH. Conditions used for qPCR were 95uC
hold for 10 mins, 40 cycles of 95uC for 10 secs, 60uC for 15 secs,
and 72uC for 20 secs.
Tumorsphere cultures
Established pancreatic cancer tumorspheres [10] were main-
tained in sphere media as described previously [19,20] with
modifications [50% NeuralBasal (Invitrogen, Carlsbad, CA), 1%
N2 Supplement (Invitrogen, Carlsbad, CA), 2% B27 supplement
(Invitrogen, Carlsbad, CA), 1% Antibiotic-Antimycotic (Invitro-
gen, Carlsbad, CA), 10 ng/mL BMP4 (Sigma), 10 ng/mL LIF
(Sigma), 20 ng/mL human bFGF-2 (Invitrogen, Carlsbad, CA), all
in 1:1 DMEM/F12 (Invitrogen, Carlsbad, CA)]. Tumorspheres
were passaged every 6 days. For passaging, tumorspheres were
dissociated with 0.05% trypsin for 2–5 min and then immediately
washed twice with 40 mL PBS. Cells were then passed through a
40 mm nylon mesh cell strainer, counted and plated in fresh sphere
medium in Costar ultra low-attachment 6 well plates (Corning,
Lowell, MA).
GSI treatment of tumorsphere cells
Tumorspheres were dissociated into single cells and re-
suspended in sphere medium containing GSI at the indicated
concentrations for the noted time periods. Cells were then
observed under a microscope or harvested for analysis.
Western blotting
Cells treated with or without GSI at various doses were lysed in
Lysis buffer (20 mM Tris pH 7.5/150 mM NaCl/12 mM
EDTA/10% glycerol/1% Triton X-100) containing a protease
inhibitor cocktail (Roche Applied Science, Indianapolis, IN) and
PhosphoStop (Roche Applied Science, Indianapolis, IN). The
protein concentration was measured using a Bio-Rad Protein
Assay (Bio-Rad, Hercules, CA). Fifty mg of protein was mixed with
an equal volume of 2x SDS loading buffer (Invitrogen, Carlsbad,
CA) and boiled for 5 min before applying the sample to SDS-
PAGE. After SDS-PAGE, the protein gel was blotted on a
nitrocellulose membrane Hybond C extra (Amersham Biosciences,
Pittsburgh, PA) using a Bio-Rad blotting apparatus (BioRad,
Hercules, CA) for one hour. The blot was blocked with 5% dry
milk in TBST for one hour, washed twice in TBST, and then
incubated with antibodies (1:1000) in 5% BSA at 4uC overnight.
The blot was washed three times in TBST and then incubated
with peroxidase-conjugated secondary antibody (Jackson Immu-
noResearch, West Grove, PA) in 5% dry milk at room
temperature for 1 hour. After washing three times in TBST, the
blot was incubated for 5 minutes with SuperSignal West Pico
Chemiluminescent Substrate (Pierce, Rockford, IL) and X-ray film
(Denville Scientific, Metuchen, NJ) was then developed.
shRNA transductioin
Lentivirus constructs pGIPZ vector containing Hes1 shRNA or
control shRNA were made in the Vector core at University of
Michigan. Transduction was performed using a ViraDuctin
Lentivirus Transduction Kit (Cell Biolabs, Inc. San Diego, CA)
as instructed.
Apoptosis assay
Tumorsphere cells transduced with control or Hes1 shRNA
were cultured in sphere media containing 4 mg/mL puromycin for
4 days followed by trypsinization and PBS washing. Cells were
filtered through a 40-mm nylon mesh to obtain single cell
suspensions. The resultant single cells were fixed with ice cold
50% ethanol in PBS overnight. Cells were then stained with PI
and FITC-annexin V using an Annexin V: FITC Apoptosis
Detection Kit II purchased from BD Biosciences (San Jose,
California).
DSL treatment of tumorspheres
Spheres were dissociated into single cells and re-suspended in
sphere medium containing DSL peptide at indicated concentra-
tions for the indicated times. Treated cells were observed under
microscope or harvested for analysis.
Ex vivo GSI treatment of tumorspheres and implantation into
NOD/SCID mice
Single cells dissociated from tumorspheres were cultured in
sphere medium containing DMSO or 8 mM GSI for 48 hours
before being dissociated with trypsin and stained with DAPI and
an antibody to H2K. Cells were sorted by FACS and DAPI
negative and H2K negative cells were collected to obtain a pure
live, human pancreatic cancer cell population. After washing with
HBSS, sorted cells were re-suspended in sphere medium. Cell
viability was validated using Trypan blue (Invitrogen, Carlsbad,
CA). Forty thousand cells in 50 mL medium were mixed with an
equal volume of Matrigel and injected subcutaneously into the
midflank region of NOD/SCID mice using a 23 gauge needle.
Five mice were injected for each treatment group. Tumor size was
measured weekly. Tumors were not allowed to exceed 2 cm in
diameter before euthanasia. Additionally, animals were monitored
daily by the University of Michigan veterinary staff and sacrificed
at any sign of distress or weight loss. At the end of the study
animals were euthanized by carbon dioxide asphyxiation followed
by cervical dislocation to ensure death.
Orthotopic Implantation of Pancreatic Tumor Cells into
NOD/SCID Mice and GSI Treatment
Pancreatic tumor cells incubated with luciferase-expressing
lentivirus overnight were washed with serum free HBSS and
suspended in a PBS/Matrigel mixture (1:1 volume) at the
concentration of 10 million cells/mL for implantation. Mice were
anesthetized with an intraperitoneal injection of 100 mg/kg
ketamine and 5 mg/kg xylazine, and a small left subcostal incision
was performed. 500,000 bulk tumor cells in a volume of 50 ml
were injected into the tail of the pancreas using a 30-gauge needle.
Buprenorphine was administered every 6 hours for the first
24 hours post-surgery to alleviate pain. Treatment with chemo-
therapy was initiated 2 weeks after tumors were detectable. Three
individual low passage human pancreatic xenograft tumors were
included in the analysis. There were 4 groups of mice: control,
RO4929097 (GSI), gemcitabine, and GSI plus gemcitabine, with
5 mice per group. Animals were evaluated by bioluminescent
imaging and tumor growth was evaluated weekly. GSI (30 mg/kg)
was administered by oral gavage at the frequency of 5 days on 2
days off. This schedule was used to minimize GSI-induced
diarrhea secondary to goblet cell hyperplasia [21]. Gemcitabine
(50 mg/kg) was delivered weekly by intraperitoneal injection as
previously described [22]. Treatment was given for 4 weeks at
which point animals were euthanized by carbon dioxide asphyx-
iation followed by cervical dislocation to ensure death. Prior to
sacrifice, animals were monitored daily by the University of
Michigan veterinary staff and sacrificed at any sign of distress or
weight loss. Necropsy was performed and tumors were excised for
analysis.
Notch Pathway in Pancreatic Cancer Stem Cells
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Bioluminescent Imaging
Bioluminescent imaging of implanted orthotopic tumors in mice
was performed using a Xenogen IVIS 200 Imaging System
(Xenogen Biosciences, Cranbury, NJ) as previously described [23].
Immunohistochemistry
Tissue samples were fixed in 10% phosphate-buffered formalin
and embedded in paraffin. Formalin-fixed, paraffin-embedded
sections were cut 4-mm thick, mounted on poly-l-lysine–coated
slides (Sigma), and dried overnight at 37uC. Sections were then
dewaxed in xylene, rehydrated according to standard histopath-
ologic procedures, and stained with H&E. Immunodetection was
done using the DakoCytomation LSAB+Kit according to manu-
facturer’s protocol (Dako, Denmark). The slides were then
counterstained with Hematoxylin and covered with VectaMount
Mounting Media (Vector Labs, Burlingame, CA). Each stained
section was then evaluated by microscopy.
Figure 1. Expression profile of Notch pathway components in cancer stem cells (CSC). A. Flow cytometry analysis. Dissociated low-
passage human pancreatic cancer xenograft cells were stained with DAPI and antibodies to H2K, ESA, CD44 and CD24. DAPI positive dead cells and
H2K positive mouse cells were both eliminated from the analysis. The CSC population (with surface marker ESA+/CD44+/CD24+) was gated by both P5
and P7, and the non-CSC population from P6. B. Transcript levels of Notch pathway components in CSC compared to in non-CSC obtained by qPCR,
normalized to GAPDH. The mean fold change between tumors is represented by a horizontal bar.
doi:10.1371/journal.pone.0091983.g001
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Figure 2. GSI treatment of pancreatic cancer cells. A. Primary pancreatic cancer cell tumorspheres (derived from patient 5) were cultured in
sphere medium containing different concentration of GSI as indicated for 48 hours before Western blot analysis with an antibody to Hes1 or b-actin.
Notch Pathway in Pancreatic Cancer Stem Cells
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TUNEL Assay
TUNEL analysis was done using the Promega TUNEL assay kit
(Promega, San Luis Obispo, CA) according to the manufacturer’s
instructions. Apoptotic cell nuclei were visualized as a yellow-green
fluorescent signal under fluorescence microscopy. Cell nuclei were
counterstained with DAPI (Vector Labs, Burlingame, CA).
Additional reagents RO4929097 for in vitro work was purchased
from Selleck Chemicals (Houston, TX).
Oligonucleotides for qRT-PCR The following sequences were used:
Hes1 59-GAGAGGCGGCTAAGGTGTTTG-39 and 59-
CTGGTGTAGACGGGGATGAC-39, GLI1 59-GGCTGGAC-
CAGCTACATCAAC-39 and 59-TGGTACCGGTGTGGGA-
CAA-39, GLI2 59-GCAAATGAAAGCCAGGGAAC-39 and 59-
ATCTCAGGAAGGCGATGAAC-39, PTCH1 59-TATCCAG-
CACTTACTTTACGACCT-39 and 59-ATCCTGAAGTCCCT-
GAAGCC39, and GAPDH 59-TCACCAGGGCTGCTTT-
TAAC-39 and 59-GACAAGCTTCCCGTTCTCAG-39.
Statistical analysis
Data are expressed as the mean 6 S.E. Statistically significant
differences were determined by Student’s t test and X2 analyses or
the Mann-Whitney U test where appropriate, and defined as P,
0.05.
Results
Notch signaling pathway is upregulated in pancreatic
cancer stem cells
The Notch signaling pathway has been shown to be activated in
pancreatic cancer cells [24]. We hypothesized that Notch signaling
pathway components may be further upregulated in the pancreatic
cancer stem cell subpopulation. Using primary human pancreatic
cancer xenografts from 8 different patient tumors we evaluated
expression levels of Notch signaling pathway components in
cancer stem cells compared to bulk tumor cells. Tumors from
xenografts were isolated and processed into single cell suspensions
that were then sorted based on the triple-marker profile CD44+/
CD24+/ESA+ to obtain CSCs and separately non-CSCs
(Figure 1A). Quantitative RT-PCR analysis of RNA obtained
from CSCs and non-CSCs for expression of components of the
Notch signaling pathway was performed. The results suggest
upregulation of Notch pathway components in CSCs above that of
non-CSCs (Figure 1B). CSCs in 6 of 8 tumors expressed at least
one Notch receptor at a level .1.5 fold over non-CSC. Similarly,
at least one Notch ligand was upregulated .1.5 fold in CSC over
non-CSC in 6 of 8 tumors. Of note, we did not detect expression
of either the Notch4 receptor of DLL3 ligand in either CSC or
non-CSC compartments in any of the primary xenografts tested
(data not shown). There was a mean 1.75 fold greater expression of
the Notch pathway target gene Hes1 in the CSCs compared to
non-CSCs. These results suggest that CSCs differentially express
increased levels of Notch pathway components and that the
pathway is correspondingly activated as shown by enhanced
expression of Hes1.
Notch pathway inhibition
Based on the observation that Notch signaling pathway
components are upregulated in pancreatic cancer and in particular
pancreatic CSC, we further studied the contribution of Notch
pathway activation to pancreatic CSC function. Gamma secretase
catalyzes the third cleavage step of the Notch receptor which
releases the Notch intracellular domain. This step allows the
Notch receptor to then translocate to the nucleus and activate
Notch signaling, resulting in upregulation of target gene expres-
sion. Inhibition of gamma secretase with a gamma secretase
inhibitor can thus block activation of the Notch signaling pathway.
Incubation of pancreatic cancer tumorspheres with increasing
doses of GSI reduced expression levels of the Notch target gene
Hes1 in a dose dependent manner (Figure 2A,B) (p,.001 vs.
control). Having confirmed that GSI can inhibit Notch signaling in
pancreatic cancer cells, we next evaluated the effect of Notch
pathway inhibition specifically on the CSC compartment.
Pancreatic cancer cells treated with GSI showed a significant
reduction in CSCs with the ESA+/CD44+/CD24+ marker profile
compared to untreated cells (2.7660.16% control vs. 1.4360.15%
with GSI p= 0.013) (Figure 2C,D). This result suggests a role for
Notch pathway activation in CSC maintenance.
One of the defining features of CSCs is self-renewal which can
be assayed in vitro by measuring tumorsphere formation through
multiple passages. Pancreatic CSCs identified with the marker
profile ESA+/CD44+/CD24+ have the ability to form spheres in
nonadherent conditions which distinguishes them from non-
cancer stem cells which lack this ability [10]. Having observed
dose dependent inhibition of the Notch pathway with increasing
doses of GSI and a resultant decrease in the percentage of
pancreatic CSC, we evaluated the functional impact on CSC
function by testing the effects of GSI in tumorsphere assays.
Consistent with a dose dependent effect on Notch pathway
inhibition, treatment of pancreatic cancer cells with GSI caused a
dose dependent decrease in primary tumorsphere formation
frequency (Figure 3A, p,.01 vs. control).
To determine if the observed inhibition of tumorsphere
formation was preserved following transient exposure to Notch
inhibition, treated tumorspheres were dissociated into single cells
and re-cultured in normal sphere media without GSI. Notably, the
effect on tumorsphere formation was preserved even after removal
of the gamma secretase inhibitor, as evidenced by decreased
generation of secondary tumorspheres (Figure 3A, p,.01 vs.
control).
An effect of GSI on apoptosis could explain this reduction in
tumorsphere formation. Indeed, we observed an increased rate of
apoptosis based on PI and AnnexinV staining of cells from in
tumorspheres treated with GSI compared to vehicle treated
tumorspheres (Figure 3B, p,.05 8 mM vs. control, p,.01 16 mM
vs. control). This result suggests that apoptosis contributes to
decreased tumorsphere forming capability of the cells treated with
GSI. We also performed cell cycle analysis in the absence and
presence of GSI which revealed increased accumulation of cells in
G1 with GSI compared to control (p,.01). Impaired cell cycle
progression may therefore also contribute to reduction in tumor-
sphere formation with inhibition of Notch signaling pathway with
GSI (Figure 3C).
In order to further validate this observed functional effect of in
vitro Notch pathway inhibition, we studied whether pretreatment
with GSI could inhibit tumor formation in vivo. In this assay, we
pre-treated pancreatic cancer cells established as tumorspheres
B. Quantitation of Hes1 mRNA levels following GSI treatment for 48 hours (*p,.001 vs. control). C. Pancreatic cancer cells in sphere medium were
treated with control vehicle (DMSO) or 8 mM GSI for 48 hours. FACS analysis of control DMSO treated cells (upper panel) and GSI treated cells (lower
panel). CSC population with surface marker of ESA+/CD44+/CD24+ was identified by those cells in both gates P5 and P7. D. Quantitation of ESA+/
CD44+/CD24+ CSC population following DMSO and GSI treatment (*p= 0.013 vs. DMSO).
doi:10.1371/journal.pone.0091983.g002
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with GSI for 48 hours and then implanted viable, treated cells
subcutaneously into NOD/SCID mice (5 mice per group). Cells
that were untreated formed tumors 5 days earlier than those
pretreated with GSI and grew significantly larger (p,.01) than
those emanating from cells pre-treated with GSI (Figure 3D).
Notch pathway inhibition using Hes1 shRNA
As observed in Figure 1B, the mRNA level of Hes1, a direct
target/effector of Notch-signaling, was upregulated in CSCs
compared to non-CSCs in several primary xenografts. Upregula-
tion of Hes1 was consistently observed across xenografts, in
contrast to other Notch targets such as Hey1 and HeyL (data not
shown). In order to assess whether the observed effects of GSI were
specifically the result of inhibiting the Notch signaling pathway
and not off-target effects, we used lentiviral constructs expressing
control and Hes1 shRNA to specifically target Hes1. Knockdown
of Hes1 by shRNA was confirmed at both the mRNA (p,.001 vs.
control) and protein levels (Figure 4A,B) and did not affect
upstream Notch1 cleavage (Figure 4B). Downregulation of Hes1
resulted in impaired tumorsphere formation (Figure 4C,D, p,
.001 vs. control) providing further evidence that Notch pathway
activation contributes to pancreatic CSC function.
Ligand activation of Notch pathway promotes
tumorsphere formation
Activation of the Notch signaling pathway is dependent on
receptor ligand activation with one of the Notch ligands. DSL is a
synthesized peptide that mimics the conserved minimum sequence
of the Notch receptor binding domain and may be used to activate
the Notch signaling pathway [25,26]. Hes1 expression increased in
a dose dependent fashion at both the mRNA (p,.001 vs. control)
and protein levels with exposure of pancreatic tumorspheres to
DSL, confirming Notch signaling pathway activation
(Figure 5A,B). Additionally, increasing levels of DSL led to
increased cleavage of Notch1 ICD (Figure 5B). DSL exposure also
led to an increase in the percentage of CD44+/CD24+/ESA+
pancreatic CSCs within tumorspheres (3.95%60.33 vs.
6.87%61.12 *p,.02 vs. control) (Figure 5C). This increase in
CSCs induced by Notch pathway activation provides further
evidence for an active role of Notch in pancreatic CSC
maintenance. We tested the functional significance of this increase
in number of CSCs by Notch pathway activation in the
tumorsphere assay. Notably, Notch pathway activation by DSL
exposure caused a dose dependent increase in tumorsphere
formation (Figure 5D,E, p,.01 vs. control). These results confirm
a functional contribution of Notch pathway activation to
pancreatic CSC maintenance and function.
GSI treatment inhibits tumor growth and decreases the
CSC population in vivo
Previous data suggests that pancreatic CSCs are more resistant
to cytotoxic chemotherapy. Targeting the CSC compartment is
thus a key strategy in any attempt to overcome this inherent
limitation of currently available chemotherapy. The results
described above provide compelling evidence for the importance
of Notch signaling pathway activation in the maintenance and
function of pancreatic CSCs. Notably, ex vivo treatment of
pancreatic cancer cells with a Notch inhibitor reduced tumorigenic
potential of the treated cells (Figure 3D). These results clearly
support the Notch pathway as a potential therapeutic target in
pancreatic cancer. To test the efficacy of targeting the Notch
pathway in vivo in established tumors, we utilized an orthotopic
pancreatic cancer model in NOD-SCID mice with low passage
primary human pancreatic cancer xenografts. We used two of the
primary pancreatic cancer xenografts profiled in Figure 1 to
establish orthotopic tumors in the pancreas of mice. The cells were
luciferase-labeled prior to implantation to allow in vivo biolumi-
nescent monitoring of tumor growth. Once tumors were
established and visible by bioluminescence (approximately 2
weeks), the mice were randomized to four treatment groups:
vehicle control, GSI (30 mg/kg) alone, gemcitabine (50 mg/kg)
alone, and a combination of GSI and gemcitabine. All mice
tolerated the different treatments equally well without significant
weight loss or noticeable change in physical activity. Mice treated
with single agent GSI or gemcitabine demonstrated slower tumor
growth during the 4-week treatment period compared to control
animals (Figure 6A). Treatment with both GSI and gemcitabine
further enhanced the inhibition, suggesting an additional benefit to
the combination. At the completion of the 4-week treatment
period, the mice were euthanized and the tumors were excised.
The final tumor weights corresponded to the bioluminescence
signal and confirmed tumor growth inhibition with treatment
(Figure 6B, p,.01 vs. control).
To confirm that observed inhibition in tumor growth was due to
Notch pathway inhibition, we performed assays on excised tumor
tissue from each of the treatment groups. We first confirmed that
oral delivery of GSI inhibited the Notch pathway activation in the
tumor cells. Tumors were processed into single cell suspensions
and subjected to FACS to separate ESA+/CD44+/CD24+ CSCs
from non-CSCs. Transcript levels of Hes1 were reduced (p,.02)
in both subpopulations as compared to control untreated tumors
(Figure 6C). As was seen with in vitro treatment of pancreatic
cancer cells with GSI (Figure 2C, D), in vivo inhibition of the Notch
pathway reduced the number of CSCs within established
orthotopic pancreas tumors (Figure 6C, p,.01 vs. control). These
results support a direct therapeutic effect of Notch pathway
inhibition in primary pancreatic cancers in an orthotopic primary
tumor model.
Figure 3. GSI treatment effect on pancreatic tumorspheres. A. Pancreatic cancer cell tumorspheres cultured for 5 days in sphere medium
containing indicated concentrations of GSI. Representative images of primary tumorspheres that developed from 1000 cells per well cultured with
increasing concentrations of GSI. Quantitation of number of primary tumorspheres (black bars) formed at each concentration with 1000 cells seeded
per well (*p,.01 vs. control). Secondary tumorsphere formation (gray bars) from tumorspheres treated with GSI were dissociated into single cells,
washed, and cultured for 5 days in normal sphere medium without GSI (**p,.01 vs. control). B. Tumorspheres treated with GSI at increasing
concentrations stained with propidium iodide (PI) and FITC-Annexin V (AnV) and analyzed by flow cytometry to evaluate the extent of apoptosis.(*p,
.05 8 mM vs. control, **p,.01 16 mM vs. control). C. Cell cycle analysis of pancreatic tumorspheres treated with DMSO control or GSI at 0, 24, 48, and
72 hrs. (*p,.01 vs. control). D. Pancreatic cancer cells cultured with either 8 mM GSI or vehicle control (DMSO) for 48 hours injected subcutaneously
into NOD/SCID mice. Representative images of mice implanted with cells from the indicated treatment groups taken 21 days after injection. Arrows
indicate location of the tumors. Serial tumor sizes measurements from mice treated with DMSO control or GSI at indicated time points. N = 5 (*p,.01
vs. control).
doi:10.1371/journal.pone.0091983.g003
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Tumor histology was examined in all the treatment groups and
was most notably altered with the combination of GSI and
gemcitabine. Untreated tumors demonstrated densely packed
cancer cells whereas combination treated tumors show evidence of
necrosis and the tumor mass was less densely populated with
cancer cells (Figure 6D). No significant difference was noted with
either treatment alone. Our previously described cell cycle analysis
following treatment with GSI in vitro suggested impaired cell cycle
progression (Figure 3C). We therefore analyzed the proliferative
index of tumors treated in vivo with GSI and confirmed a decrease
in Ki67+ cells in tumors treated with GSI (p,.01 vs. control), an
effect that was augmented with the addition of gemcitabine
(Figure 6D and Figure S1). Having also shown by FACS analysis
of in vitro treated cells that GSI increased apoptosis, we analyzed
Figure 4. Hes1 shRNA treatment effect on pancreatic tumorspheres. A. Pancreatic cancer cells transduced with either control or Hes1 shRNA
harvested after culturing for 4 days. Hes1 transcript levels quantitated by qRT-PCR, normalized to GAPDH (*p,.001 vs. control). B. Cell lysates were
Western blotted for Hes1, Notch1, cleaved Notch1, or b-actin. C. Representative images of tumorspheres generated from pancreatic cancer cells
transduced with either control scramble sequence or shRNA to Hes1 cultured for 5 days. D. Quantitation of number of tumorspheres generated per
1000 cells plated (*p,.001 vs. control).
doi:10.1371/journal.pone.0091983.g004
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our in vivo treated tumors by TUNEL and further confirmed
increased apoptosis in tumors treated with GSI (Figure 6D, p,
.001 vs. control). The level of apoptosis in response to GSI was
similar to that achieved with gemcitabine indicating that Notch
signaling regulates both survival and proliferative pathway in
PDAC. Tumors treated with combination of both GSI and
gemcitabine had the highest amount of apoptosis suggesting
enhanced efficacy of the combination. In addition to the direct
effects seen with GSI alone, this latter result may reflect greater
sensitivity to gemcitabine in a broader range of cancer cells due to
inhibition of the Notch signaling pathway.
Discussion
Pancreatic cancer is notoriously difficult to treat in part due to
late detection, early spread, and resistance to therapy. Standard
cytotoxic chemotherapy is provided with the intent to control
disease but is well characterized to fall short of a clinically
significant impact. While inherent heterogeneity of genetic
Figure 5. Notch pathway activation with DSL peptide stimulates tumorsphere formation and increased CSC population. A.
Pancreatic cancer cell tumorspheres were cultured in sphere medium containing increasing concentration of DSL peptide as indicated for 5 days.
mRNA levels of Hes1 from treated tumorspheres were analyzed by qRT-PCR and normalized to internal control GAPDH (*p,.001 vs. control). B.
Tumorspheres cultured as in A. were Western blotted for cleaved-Notch1, Notch1, Hes1 or b-actin. C. Pancreatic cancer cells cultured in sphere
medium containing increasing concentration of DSL analyzed for percentage of CSC by FACS analysis of cells stained with DAPI and antibodies to
ESA, CD44, and CD24. Percentage of CSC represents ESA+/CD44+/CD24+ cells as a percentage of live DAPI-negative cells (*p,.02 vs. control). D+E.
Tumorsphere formation assay performed on pancreatic cancer cells cultured in increasing concentration of DSL peptide. Representative images
shown in D. with quantitation of number of tumorspheres per 1000 cells plated shown in E. (*p,.01 vs. control).
doi:10.1371/journal.pone.0091983.g005
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Figure 6. GSI treatment slowed tumor growth in an orthotopic model of primary pancreatic cancer. A. Representative images of tumors
monitored using bioluminescent imaging. Fold change in bioluminescence of tumors over time from day of implantation. B. Images of tumors
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changes within a tumor may explain differential sensitivity to
chemotherapy, recent evidence supports the existence of a
hierarchy of pancreatic cancer cells that contain a subpopulation
of cells possessing stem cell characteristics like self-renewal. Self-
renewal of normal stem cells has been shown to be dependent on
several developmental signaling pathways including Wnt, Hedge-
hog and Notch [27–29]. These same developmental pathways
have been notably reported to be upregulated in CSCs and to
contribute to CSC function. We have previously shown that the
Hedgehog ligand expression is upregulated in pancreatic CSCs
over the already increased expression in bulk pancreatic cancer
cells [10]. In the current study, we demonstrate that the Notch
pathway is also further upregulated in the CSC compartment in
comparison to bulk pancreatic cancer cells. Interestingly, although
the Notch pathway has been shown to regulate the Hedgehog
pathway through repression of GLI1 by Hes1 [30], we did not
observe significant changes in Hedgehog signaling components
when Notch signaling was inhibited (Figure S2A,B). The Notch
pathway therefore represents a promising therapeutic target for
pancreatic cancer.
Identification that a pathway is differentially up-regulated in
cancer is clearly only the first step in determining its functional role
in tumor growth. The concept of driver mutations versus
passenger mutations reflects an observation that not all differential
changes are necessarily sufficient for promoting tumor growth and
metastatic behavior. The Notch pathway was recently identified as
one of 12 core signaling pathways consistently altered in
pancreatic cancer [31]. The role of the Notch pathway in
development and its importance in normal stem cell maintenance
points to potential importance in pancreatic CSC maintenance as
well, and potential value of targeting this pathway in pancreatic
CSCs has been proposed by some [32]. The results of the studies
reported here validate the importance of Notch activation in
pancreatic CSC maintenance. We utilized a novel inhibitor of
gamma secretase to demonstrate that the Notch signaling pathway
can be effectively targeted in pancreatic cancer cells. Inhibition of
the Notch signaling pathway led to a decrease in CSC number and
impaired CSC function. These effects were functionally relevant as
the induced effects of Notch inhibition with a gamma secretase
inhibitor decreased the ability of treated cancer cells to form
tumors. Notably, we found that the effects of the gamma secretase
inhibitor on CSC number (p,.05 vs. control) persisted weeks the
drug was withdrawn (Figure S3), indicating a relatively stable
response to pathway inhibition. The specificity of the observed
effects due to gamma secretase inhibition was shown by attaining
similar results in vitro through direct down-regulation of a Notch
pathway target gene Hes1 with shRNA. Taken together, our
results support that Notch pathway activation is necessary for
pancreatic CSC maintenance and function. Notch receptor
activation with the DSL synthetic ligand which directly activates
the Notch signaling pathway, resulted in increased CSC number
and function, as measured by tumorsphere formation.
Demonstrating that inhibiting the Notch pathway has functional
consequences thus provides further evidence that this pathway is
not only differentially expressed but plays a causative role in tumor
growth. Ultimately, an observed pathway upregulation is only a
useful therapeutic target if it can be shown that inhibiting it leads
to tumor response. But chemotherapy alone has the potential to
cause tumor response and yet clinical efficacy is again limited. In
the CSC model, despite the sensitivity of bulk tumor cells to
chemotherapy, CSCs are resistant and lead ultimately to the
failure of cytotoxic chemotherapy. Targeting the Notch pathway
leads to a tumor response as evidenced by the results of in vivo
treatment of established orthotopic human pancreatic tumors with
a gamma secretase inhibitor. These results are consistent with a
recent study using a different gamma secretase inhibitor, PF-
03084014, which also depleted pancreatic CSCs and enhanced the
efficacy of gemcitabine in vivo [33]. These observations of
synergistic effects of combining Notch pathway inhibition with
chemotherapy provide insight into the potential of strategically
targeting both CSCs and bulk tumor cells.
The potential clinical utility of such an approach carries much
promise as one can clearly envision the clinical utility of targeting
Notch pathway signaling for all stages of pancreatic cancer. In the
setting of resectable disease, the observed high frequency of distant
relapse following successful surgery suggests spread of cancer cells
prior to surgery. CSCs have been shown to not only be resistant to
therapy but also to have increased metastatic potential. By
providing therapy to patients with resectable disease that targets
CSCs through Notch inhibition, the subset of cancer cells
responsible for recurrent disease and progression to an incurable
state may be targeted. Prevention of pancreatic cancer metastasis
by PF-03084014 gives credence to this idea [33]. In the advanced
setting where disease is clinically evident in distant organs,
systemic therapy is provided with palliative intent as it is well-
established that chemotherapy can at best control disease for a
period of time before eventual progression. CSCs may participate
in this pattern of failure. Clinical benefit seen with bulk tumor
reduction using standard chemotherapy could be greatly aug-
mented by targeting CSCs to delay or even prevent this failure.
Our study provides compelling preclinical evidence that such a
strategy can be implemented in the treatment of pancreatic cancer
and supports further exploration of targeting Notch signaling to
target pancreatic CSCs in clinical trial design.
Supporting Information
Figure S1 Ki67 staining of GSI and gemcitabine treated
xenografts. Ki67 stained sections from tumors treated with GSI,
gemcitabine, or combination of GSI and gemcitabine. Images
were taken in 40x field and are representative of 5 random sections
from each of 3 tumors per treatment group.
(TIF)
Figure S2 Effects of HES1 knockdown and GSI on
Hedgehog signaling. A. Tumorsphere cells were transduced
with either a non-targeting control shRNA or an shRNA targeting
Hes1. Quantitative RT-PCR analysis of fold change in Hes1 and
Hedgehog pathway components GLI1, GLI2, and PTCH1,
excised at the completion of 4 weeks of treatment for each treatment group. Final tumor weights (in grams) of the excised tumors (*p,.01 vs.
control). C. (upper panel) mRNA harvested from tumors excised at completion of 4 weeks of treatment was analyzed by qRT-PCR for Hes1, shown
normalized to GAPDH (*p,.02 vs. control). (Lower panel) Single cells were isolated from tumors excised at completion of treatment were analyzed for
percentage of CSC by FACS analysis of cells stained with DAPI and antibodies to H2k, ESA, CD44, and CD24. Percentage of CSC represents ESA+/
CD44+/CD24+ cells as a percentage of live DAPI-negative and human H2k-negative cells (*p,.01 vs. control). D. H+E stained sections from tumors
treated with GSI, gemcitabine, or combination of GSI and gemcitabine. Proliferative index calculated as number of Ki67+ stained cells from formalin-
fixed sections of tumor treated with drug. Graph representing mean number of Ki67+ cells per 40x field from 5 random sections from each of 3
tumors per treatment group (*p,.01 vs. control). TUNEL assay performed on sections of tumor treated in vivo and tabulated mean number of
TUNEL+ apoptotic cells (*p,.001 vs. control).
doi:10.1371/journal.pone.0091983.g006
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normalized to a GAPDH control, are represented as vertical bars
+/- SEM. Corresponding p-values between conditions are
indicated. B. Primary PDAC cells were treated with
RO4929097 (1 mM) or DMSO for 24 hours, after which mRNA
was collected. Quantitative RT-PCR was performed and analyzed
as in A. Corresponding p-values between conditions are indicated.
(TIF)
Figure S3 Effects of GSI withdrawal on CSC subpopu-
lation. Primary tumor xenografts were established subcutaneous-
ly in NOD/SCID mice. Animals were treated daily with 30 mg/
kg RO4929097 (5 mice) or vehicle (4 mice), 5 days on 2 days off,
for 2 weeks. Tumor cells were harvested and expression of CD44,
CD24 and ESA were analyzed by flow cytometry. An additional
animal group (5 mice) was treated with 30 mg/kg RO4929097,
5 days on 2 days off, for 2 weeks, after which the treatment
was ceased for 2 additional weeks. Tumor cells were harvested
and analyzed by flow cytometry. Percent of cells co-expressing
CD44, CD24 and ESA in each group is represented as vertical
bars +/2 SEM. Corresponding p-values between conditions are
indicated.
(TIF)
Checklist S1 ARRIVE Guidelines Checklist.
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